X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (45502) 45502
Publication (2857) 2857
Newsletter (371) 371
Book Review (253) 253
Magazine Article (171) 171
Book Chapter (88) 88
Conference Proceeding (47) 47
Book / eBook (38) 38
Dissertation (13) 13
Newspaper Article (13) 13
Web Resource (9) 9
Reference (6) 6
Data Set (3) 3
Paper (2) 2
Trade Publication Article (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28139) 28139
male (23815) 23815
vasodilator agents - pharmacology (19166) 19166
animals (18750) 18750
female (15629) 15629
vasodilator agents - therapeutic use (14445) 14445
middle aged (10682) 10682
index medicus (8653) 8653
rats (8600) 8600
adult (8284) 8284
aged (7519) 7519
vasodilator agents - administration & dosage (7401) 7401
cardiac & cardiovascular systems (6797) 6797
pharmacology & pharmacy (5769) 5769
dose-response relationship, drug (4695) 4695
in vitro techniques (4694) 4694
vasodilation - drug effects (4601) 4601
blood pressure - drug effects (4540) 4540
vasodilator agents (4326) 4326
nitric oxide (3797) 3797
peripheral vascular disease (3415) 3415
treatment outcome (3405) 3405
time factors (3231) 3231
nitric-oxide (3184) 3184
acetylcholine - pharmacology (3159) 3159
dogs (3141) 3141
hemodynamics - drug effects (3107) 3107
vasodilators (2955) 2955
endothelium, vascular - drug effects (2773) 2773
hypertension (2730) 2730
rats, sprague-dawley (2711) 2711
vasodilator agents - adverse effects (2672) 2672
endothelium (2666) 2666
rats, wistar (2636) 2636
physiology (2582) 2582
vasoconstrictor agents - pharmacology (2565) 2565
nitroprusside - pharmacology (2498) 2498
muscle, smooth, vascular - drug effects (2385) 2385
heart failure - drug therapy (2205) 2205
rabbits (2182) 2182
heart rate - drug effects (2158) 2158
vasodilation (2123) 2123
surgery (1991) 1991
nitric oxide - metabolism (1936) 1936
mice (1889) 1889
vascular resistance - drug effects (1814) 1814
enzyme inhibitors - pharmacology (1806) 1806
blood pressure (1793) 1793
acetylcholine (1727) 1727
coronary vessels - drug effects (1723) 1723
drug therapy, combination (1699) 1699
hypertension, pulmonary - drug therapy (1671) 1671
hypertension - drug therapy (1662) 1662
research (1653) 1653
vasoconstriction - drug effects (1643) 1643
nitroglycerin - pharmacology (1635) 1635
regional blood flow - drug effects (1630) 1630
vasodilation - physiology (1595) 1595
risk factors (1594) 1594
disease models, animal (1581) 1581
double-blind method (1557) 1557
sildenafil citrate (1548) 1548
prospective studies (1524) 1524
endothelium, vascular - physiopathology (1518) 1518
coronary circulation - drug effects (1485) 1485
hemodynamics (1483) 1483
blood vessels (1456) 1456
medicine, general & internal (1445) 1445
endothelium, vascular - physiology (1424) 1424
nitroglycerin (1421) 1421
smooth-muscle (1408) 1408
adenosine (1402) 1402
adolescent (1391) 1391
electrocardiography (1383) 1383
blood-flow (1346) 1346
dilatation (1342) 1342
analysis (1329) 1329
care and treatment (1314) 1314
antihypertensive agents - therapeutic use (1310) 1310
hypertension - physiopathology (1283) 1283
respiratory system (1254) 1254
medicine & public health (1252) 1252
aged, 80 and over (1251) 1251
prognosis (1221) 1221
therapy (1212) 1212
adrenergic beta-antagonists - therapeutic use (1207) 1207
follow-up studies (1199) 1199
administration, oral (1197) 1197
ischemia (1191) 1191
arteries (1174) 1174
endothelium, vascular - metabolism (1171) 1171
heart failure - physiopathology (1171) 1171
disease (1170) 1170
nitroglycerin - therapeutic use (1161) 1161
drug therapy (1159) 1159
muscle contraction - drug effects (1158) 1158
pulmonary hypertension (1158) 1158
cardiology (1156) 1156
cells (1155) 1155
physiological aspects (1147) 1147
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38379) 38379
German (1962) 1962
French (1293) 1293
Russian (1267) 1267
Italian (722) 722
Japanese (661) 661
Chinese (478) 478
Spanish (450) 450
Polish (230) 230
Portuguese (105) 105
Hungarian (98) 98
Romanian (78) 78
Czech (76) 76
Dutch (67) 67
Danish (52) 52
Ukrainian (52) 52
Swedish (44) 44
Turkish (33) 33
Norwegian (32) 32
Bulgarian (23) 23
Finnish (22) 22
Croatian (19) 19
Serbian (12) 12
Slovak (12) 12
Lithuanian (10) 10
Hebrew (8) 8
Korean (5) 5
Bosnian (1) 1
Greek (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mini-Reviews in Medicinal Chemistry, ISSN 1389-5575, 2008, Volume 8, Issue 6, pp. 538 - 554
Journal Article
Mini-Reviews in Medicinal Chemistry, ISSN 1389-5575, 2014, Volume 14, Issue 4, pp. 355 - 369
In the present article synthesis and medicinal applications of [1, 2, 4] oxadiazoles are reviewed. The oxadiazoles have a wide range of applications such as... 
Heterocycles | Anti-tumor agents | Synthetic methods | Anti-inflammatory | [1,2,4] oxadiazoles | Anaesthetic angent | One pot synthesis | CONVENIENT SYNTHESIS | CHEMISTRY, MEDICINAL | NONQUATERNARY CHOLINESTERASE REACTIVATORS | ONE-POT SYNTHESIS | 2,5-DISUBSTITUTED 1,3,4-OXADIAZOLES | MICROWAVE IRRADIATION | ACETYLCHOLINESTERASE INVITRO | anti-tumor agents | one pot synthesis | SOLVENT-FREE | heterocycles | anti-inflammatory | ANTIPROTOZOAL ACTIVITY | synthetic methods | 1,2,4-OXADIAZOLE DERIVATIVES | PHARMACOLOGICAL-PROPERTIES | Fibrinolytic Agents - chemistry | Vasodilator Agents - therapeutic use | Apoptosis - drug effects | Antineoplastic Agents - chemical synthesis | Anesthetics - pharmacology | Hypersensitivity - drug therapy | Antineoplastic Agents - toxicity | Platelet Aggregation Inhibitors - chemical synthesis | Oxadiazoles - pharmacology | Fibrinolytic Agents - therapeutic use | Anesthetics - chemical synthesis | Platelet Aggregation Inhibitors - pharmacology | Vasodilator Agents - chemical synthesis | Fibrinolytic Agents - chemical synthesis | Blood Platelets - drug effects | Oxadiazoles - chemistry | Venous Thrombosis - drug therapy | Anesthetics - chemistry | Anti-Inflammatory Agents - pharmacology | Antineoplastic Agents - chemistry | Oxadiazoles - therapeutic use | Animals | Anti-Inflammatory Agents - chemistry | Platelet Aggregation Inhibitors - chemistry | Vasodilator Agents - chemistry | Anti-Inflammatory Agents - chemical synthesis
Journal Article
Nutrients, ISSN 2072-6643, 07/2018, Volume 10, Issue 7, p. 921
Diminished bioavailability of nitric oxide (NO), the gaseous signaling molecule involved in the regulation of numerous vital biological functions, contributes... 
Hypertension | Obesity | Watermelon | Liver | Cardiovascular disease | Inflammation | Adipocytes | Endothelial function | Supplements | Enterocytes | Mitochondria | Interventions | Arginine | Nitric oxide | Flow mediated dilation | Therapeutics | Aging | Insulin resistance | Muscle | Diabetes | Immune cells | DEPENDENT DIABETES-MELLITUS | therapeutics | NITRIC-OXIDE SYNTHESIS | L-ARGININE SUPPLEMENTATION | PRESERVED EJECTION FRACTION | enterocytes | HUMAN SKELETAL-MUSCLE | NUTRITION & DIETETICS | arginine | inflammation | muscle | CULTURED ENDOTHELIAL-CELLS | MUSCLE PROTEIN ANABOLISM | watermelon | adipocytes | insulin resistance | obesity | endothelial function | cardiovascular disease | nitric oxide | ORAL L-CITRULLINE | liver | SPONTANEOUSLY HYPERTENSIVE-RATS | mitochondria | immune cells | CHAIN AMINO-ACIDS | supplements | interventions | aging | hypertension | diabetes | flow mediated dilation | Vasodilator Agents - therapeutic use | Hypoglycemic Agents - metabolism | Antioxidants - metabolism | Humans | Citrulline - metabolism | Metabolic Syndrome - metabolism | Antihypertensive Agents - metabolism | Diabetic Angiopathies - physiopathology | Vasodilator Agents - metabolism | Metabolic Syndrome - physiopathology | Hypertension - prevention & control | Metabolic Syndrome - immunology | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Diabetic Angiopathies - prevention & control | Dietary Supplements - adverse effects | Vascular Stiffness | Sarcopenia - metabolism | Endothelium, Vascular - immunology | Hypoglycemic Agents - therapeutic use | Diabetic Angiopathies - metabolism | Sarcopenia - immunology | Endothelium, Vascular - physiopathology | Insulin Resistance | Metabolic Syndrome - therapy | Hypertension - immunology | Citrulline - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Citrulline - adverse effects | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Antioxidants - therapeutic use | Sarcopenia - physiopathology | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Endothelium, Vascular - metabolism | Models, Biological | Sarcopenia - prevention & control | Diabetic Angiopathies - immunology | Antioxidants - adverse effects | Vasodilator Agents - adverse effects | Hypoglycemic Agents - adverse effects | Health | Dietary supplements | Muscles | Amino acids | Gastrointestinal tract | Bioavailability | Citrulline | Metabolism | Nitric-oxide synthase | Substrates | Urea | L-citrulline | Synthesis | Gastrointestinal system | Blood pressure | Adults | Supplementation | Age
Journal Article
Journal Article
Research Paper - Effect of redox agents on the response of rat aorta to nitric oxide and sodium nitroprusside, 12/2006
Objective: To study the redox regulation of vascular responses to endogenous nitric oxide (NO) and NO derived from nitrovasodilator sodium nitroprusside (SNP)... 
Reducing agents, vasodilators, vitamin C
Journal
Trends in Pharmacological Sciences, ISSN 0165-6147, 2011, Volume 32, Issue 12, pp. 700 - 707
Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from... 
Advanced Basic Science | INTIMA-MEDIA THICKNESS | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | ESTER TRANSFER PROTEIN | MULTIPLE-SCLEROSIS | MOLECULAR-IDENTIFICATION | CHOLESTEROL EFFLUX | ENDOTHELIAL-CELLS | PHARMACOLOGY & PHARMACY | PROSTAGLANDIN D-2 | EXTENDED-RELEASE NIACIN | HIGH-DENSITY-LIPOPROTEIN | Flushing - metabolism | Receptors, G-Protein-Coupled - metabolism | Vasodilator Agents - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Receptors, G-Protein-Coupled - agonists | Niacin - pharmacology | Niacin - therapeutic use | Niacin - adverse effects | Flushing - chemically induced | Immunosuppressive Agents - pharmacology | Langerhans Cells - drug effects | Neutrophils - metabolism | Macrophages - immunology | Hypolipidemic Agents - adverse effects | Receptors, Nicotinic - metabolism | Atherosclerosis - drug therapy | Atherosclerosis - immunology | Vasodilator Agents - pharmacology | Neutrophils - drug effects | Neutrophils - immunology | Hypolipidemic Agents - pharmacology | Atherosclerosis - metabolism | Macrophages - metabolism | Animals | Signal Transduction - drug effects | Immunosuppressive Agents - adverse effects | Macrophages - drug effects | Hypolipidemic Agents - therapeutic use | Vasodilator Agents - adverse effects | Langerhans Cells - metabolism | Atherosclerosis - prevention & control | Multiple sclerosis | Psoriasis | Health aspects | Niacin | Atherosclerosis
Journal Article
Acta Pharmaceutica, ISSN 1330-0075, 12/2016, Volume 66, Issue 4, pp. 449 - 469
Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease. Niacin... 
cardiovascular mortality/morbidity | niacin | pleiotropic effects | dyslipidemia | HCA2 receptor | RANDOMIZED CONTROLLED-TRIALS | PLASMA ADIPONECTIN LEVELS | FATTY LIVER-DISEASE | LOW HDL CHOLESTEROL | HIGH-DENSITY-LIPOPROTEIN | PHARMACOLOGY & PHARMACY | CONGESTIVE-HEART-FAILURE | TYPE-2 DIABETES-MELLITUS | CORONARY-ARTERY-DISEASE | EXTENDED-RELEASE NIACIN | CHRONIC-RENAL-FAILURE | Receptors, G-Protein-Coupled - metabolism | Vasodilator Agents - therapeutic use | Humans | Niacin - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Atherosclerosis - etiology | Fibrinolytic Agents - adverse effects | Drug Therapy, Combination - adverse effects | Niacin - therapeutic use | Fibrinolytic Agents - therapeutic use | Niacin - adverse effects | Hyperlipidemias - physiopathology | Hypolipidemic Agents - adverse effects | Receptors, Nicotinic - metabolism | Vasodilator Agents - pharmacology | Hyperlipidemias - metabolism | Atherosclerosis - chemically induced | Hyperlipidemias - drug therapy | Hypolipidemic Agents - pharmacology | Atherosclerosis - metabolism | Disease Progression | Fibrinolytic Agents - pharmacology | Antioxidants - therapeutic use | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Models, Biological | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Receptors, G-Protein-Coupled - antagonists & inhibitors | Antioxidants - adverse effects | Hypolipidemic Agents - therapeutic use | Vasodilator Agents - adverse effects | Atherosclerosis - prevention & control
Journal Article
Journal Article
Journal Article